The Japan Times - Wellgistics Health and Kare PharmTech Execute Joint Venture Expanding Access to 200,000+ Patient Lives

EUR -
AED 4.095701
AFN 72.480008
ALL 90.882712
AMD 401.805034
ANG 1.995737
AOA 1023.635334
ARS 1721.721299
AUD 1.622157
AWG 2.007127
AZN 1.900047
BAM 1.951697
BBD 2.245579
BDT 138.86805
BGN 1.948955
BHD 0.420772
BIF 3356.362879
BMD 1.115071
BND 1.428792
BOB 13.374482
BRL 6.138357
BSD 1.114956
BTN 104.659009
BWP 15.359741
BYN 3.339105
BYR 21855.38619
BZD 2.242466
CAD 1.573756
CDF 2586.964483
CHF 0.914881
CLF 0.027698
CLP 1090.127033
CNY 7.444774
CNH 7.440667
COP 3625.685911
CRC 505.646021
CUC 1.115071
CUP 26.76054
CVE 110.842372
CZK 24.346956
DJF 198.170808
DKK 7.480457
DOP 67.740985
DZD 152.081196
EGP 59.957114
ERN 16.726061
ETB 179.75372
FJD 2.514764
FKP 0.826997
GBP 0.834821
GEL 2.893653
GGP 0.826997
GHS 13.029646
GIP 0.826997
GMD 83.077063
GNF 9876.743229
GTQ 8.520088
GYD 233.749058
HKD 8.744552
HNL 30.190584
HRK 7.547925
HTG 146.132606
HUF 363.51345
IDR 20192.258205
ILS 3.552538
IMP 0.826997
INR 104.869336
IQD 1688.217076
IRR 2108992.359359
ISK 136.919964
JEP 0.826997
JMD 176.947992
JOD 0.790629
JPY 176.744329
KES 144.903869
KGS 97.510486
KHR 4549.488945
KMF 492.86165
KPW 1003.563608
KRW 1520.737678
KWD 0.346765
KYD 0.929309
KZT 499.776184
LAK 25094.667032
LBP 99854.583719
LKR 370.763872
LRD 189.90075
LSL 18.465996
LTL 3.292514
LVL 0.674496
LYD 7.170329
MAD 10.880307
MDL 19.93044
MGA 5123.750363
MKD 61.556144
MMK 2341.596043
MNT 4016.453808
MOP 9.000882
MRU 44.882019
MUR 52.442198
MVR 17.176258
MWK 1936.878232
MXN 20.768572
MYR 4.528864
MZN 71.257178
NAD 18.465992
NGN 1502.23485
NIO 40.823159
NOK 10.548462
NPR 167.454215
NZD 2.010586
OMR 0.428348
PAB 1.115031
PEN 3.838635
PGK 5.008941
PHP 70.369926
PKR 308.456482
PLN 4.399568
PYG 6968.50605
QAR 4.062245
RON 5.343646
RSD 117.7359
RUB 91.352798
RWF 1644.729318
SAR 4.18675
SBD 8.974739
SCR 15.631155
SDG 670.719139
SEK 11.033072
SGD 1.430194
SHP 0.835103
SLE 25.591287
SLL 23382.48045
SOS 637.267002
SRD 41.908265
STD 23079.712667
STN 24.8382
SVC 9.75549
SYP 14498.149201
SZL 18.465983
THB 37.411034
TJS 10.285553
TMT 3.902748
TND 3.329048
TOP 2.684822
TRY 55.9111
TTD 7.561104
TWD 36.546782
TZS 2946.578434
UAH 50.509358
UGX 4560.432794
USD 1.115071
UYU 44.855697
UZS 13380.84906
VES 999.456181
VND 28526.296796
VUV 133.26585
WST 3.098241
XAF 655.957
XAG 0.021465
XAU 0.000274244363
XCD 3.013535
XCG 2.009331
XDR 0.788413
XOF 655.957
XPF 119.331742
YER 263.853652
ZAR 18.419263
ZMK 10036.978597
ZMW 22.65679
ZWL 359.052318
SSP 6406.300033
MXV 2.336546
  • RYCEF

    0.1000

    19.81

    +0.5%

  • VOD

    -0.2500

    16.33

    -1.53%

  • CMSC

    -0.2800

    20.12

    -1.39%

  • RBGPF

    -2.0000

    65

    -3.08%

  • RIO

    -0.2500

    94.16

    -0.27%

  • BTI

    -1.2000

    54.85

    -2.19%

  • NGG

    -0.3000

    74.94

    -0.4%

  • GSK

    -0.3500

    49.35

    -0.71%

  • BCE

    -0.4200

    20.14

    -2.09%

  • CMSD

    -0.3400

    19.93

    -1.71%

  • BP

    -0.9100

    43.52

    -2.09%

  • RELX

    0.1700

    33.24

    +0.51%

  • BCC

    -0.6200

    75.97

    -0.82%

  • AZN

    -1.9400

    164.21

    -1.18%

  • JRI

    0.0000

    10.77

    0%

Wellgistics Health and Kare PharmTech Execute Joint Venture Expanding Access to 200,000+ Patient Lives
Wellgistics Health and Kare PharmTech Execute Joint Venture Expanding Access to 200,000+ Patient Lives

Wellgistics Health and Kare PharmTech Execute Joint Venture Expanding Access to 200,000+ Patient Lives

  • Joint venture executed combining Wellgistics Hub and KareRx Hub technology and operations

  • Integrated platform accelerates pharmaceutical access, fulfillment, and commercialization

  • Combined ecosystem provides potential reach to an estimated 200,000+ patient lives across pharmaceutical and provider networks

Text size:

TAMPA, FL / ACCESS Newswire / April 14, 2026 / Wellgistics Health, Inc. (NASDAQ:WGRX) ("Wellgistics" or the "Company"), a leading healthcare technology and pharmaceutical distribution company, today announced the execution of a definitive joint venture agreement with Kare PharmTech's wholly owned subsidiary, Kare Rx Hub, LLC ("KareRx"), an artificial intelligence (AI)-driven digital hub supporting retail pharmacy, telemedicine, and specialty pharmaceutical programs.

The execution of the joint venture formalizes the previously announced non-binding letter of intent and represents a significant milestone in aligning both organizations' technology platforms and operational teams into a unified ecosystem designed to accelerate patient access and improve the efficiency of pharmaceutical commercialization. By integrating the Wellgistics Hub technology stack including proprietary platforms EinsteinRx™ and HubRx AI™ with KareRx's digital hub, the combined platform is positioned to streamline the prescription journey from intake through fulfillment.

Prashant Patel, Chief Executive Officer of Wellgistics Health, commented, "This joint venture reflects our continued focus on building an integrated, technology-enabled platform to improve coordination across the prescription journey and support patient access to therapies. By combining KareRx's provider connectivity and digital engagement capabilities with our infrastructure, we believe this collaboration enhances operational efficiency and supports manufacturers and other healthcare stakeholders in navigating access pathways more effectively."

The joint venture aligns clinical, operational, and commercial teams across both organizations, enabling more seamless coordination between providers, pharmacies, and patients. Through this integration, the platform enhances key capabilities including eligibility and benefits verification, prior authorization workflows, prescription routing, and direct-to-patient fulfillment. The combined ecosystem includes a growing national footprint of independent pharmacies, provider networks, and telehealth channels, with the ability to reach more than 200,000 patient lives based on third-party internal estimates.

Mital Panera, Founder and Chief Executive Officer of KareRx, added, "KareRx was developed to connect providers, pharmacies, and patients through technology-driven solutions. This joint venture allows us to extend those capabilities by leveraging Wellgistics' technology stack, pharma expertise, and operational infrastructure. We believe the combined platform will support improved connectivity across stakeholders and facilitate access to therapies across participating networks."

The collaboration further strengthens direct-to-patient (DTP) and decentralized care models, providing pharmaceutical manufacturers with a comprehensive platform that integrates access, affordability, and fulfillment into a single solution. Leveraging AI-driven insights and a fully integrated operational backbone, the joint venture is designed to reduce barriers to therapy initiation, improve adherence, and deliver enhanced visibility into patient access and program performance.

The joint venture remains subject to customary implementation steps, and there can be no assurance regarding the timing or extent of operational integration or the realization of anticipated benefits. Additional details regarding the joint venture agreement will be provided in a Current Report on Form 8-K to be filed by the Company with the U.S. Securities and Exchange Commission.

About Wellgistics Health, Inc.

Wellgistics Health (NASDAQ:WGRX) is a health information technology leader, integrating proprietary pharmacy dispensing optimization artificial intelligence platform EinsteinRx™ into its patented blockchain-enabled smart contracts platform PharmacyChain™ to optimize the prescription drug dispensing journey. Its integrated platform connects 6,500+ pharmacies (the "Wellgistics Pharmacy Network") and 200+ manufacturers, offering wholesale distribution, digital prescription routing, direct-to-patient delivery, and AI-powered hub services such as eligibility, adherence, onboarding, prior authorization, and cash-pay fulfillment as needed to optimize patient access. Wellgistics provides end-to-end solutions designed to restore access, transparency, and trust in the U.S. prescription drug market for independent pharmacies.

About Kare PharmTech, LLC

Kare Rx Hub is an artificial intelligence (AI)-based digital hub for retail pharmacies, telemedicine portal, and specialty pharmaceutical 'lite' branded products with over 500 physician-provider relationships, 200 independent pharmacy relationships that market unique specialty pharmaceutical 'lite' products. Kare Rx Hub is owned by Kare Pharmtech, LLC, a company controlled by Dr. Kiran Patel. Dr. Patel founded Medicaid provider WellCare in 1992 and sold it in 2002 for $200 million. In 2007, Dr. Patel founded America's 1st Choice Holdings and acquired Freedom Health and Optimum Holdings. In 2017, he sold America's 1st Choice Holdings to Anthem, Inc. Dr. Patel is a noted philanthropist and was named Floridian of the Year by Florida Trend Magazine.

Forward-Looking Statements

This press release may contain forward-looking statements. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When Wellgistics Health uses words such as "may," "will," "intend," "should," "believe," "expect," "anticipate," "project," "estimate," or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. These forward-looking statements include, without limitation, statements regarding Wellgistics Health's strategy and descriptions of its future operations, prospects, and plans. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause actual results to differ materially. Additional factors are discussed in Wellgistics Health's filings with the SEC, available at www.sec.gov.

Wellgistics Media & Investor Contact
Media: [email protected]
Investor Relations: [email protected]

SOURCE: Wellgistics Health, Inc.



View the original press release on ACCESS Newswire

M.Sugiyama--JT